

## Research

### Corresponding author

Edward G. Dudley, PhD

Associate Professor of Food Science  
Department of Food Science and Center  
for Immunology and Infectious Disease  
Penn State University  
University Park, Pennsylvania, USA  
Tel. +1-814-867-0439  
Fax: +1-814-863-6132  
E-mail: [dudley@psu.edu](mailto:dudley@psu.edu)

Volume 3 : Issue 1

Article Ref. #: 1000AFTNSOJ3139

### Article History

Received: March 18<sup>th</sup>, 2017

Accepted: May 16<sup>th</sup>, 2017

Published: May 17<sup>th</sup>, 2017

### Citation

Xiaolia L, Dudley EG. A quantitative enzyme-linked immunosorbent assay for shiga toxin 2a requiring only commercially available reagents. *Adv Food Technol Nutr Sci Open J*. 2017; 3(1): 6-14. doi: [10.17140/AFTNSOJ-3-139](https://doi.org/10.17140/AFTNSOJ-3-139)

### Copyright

©2017 Dudley EG. This is an open access article distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

# A Quantitative Enzyme-Linked Immunosorbent Assay for Shiga Toxin 2a Requiring Only Commercially Available Reagents

Lingzi Xiaoli, PhD<sup>1</sup>; Edward G. Dudley, PhD<sup>1,2\*</sup>

<sup>1</sup>Department of Food Science, Penn State University, University Park, Pennsylvania, USA

<sup>2</sup>Center for Immunology and Infectious Disease, Penn State University, University Park, Pennsylvania, USA

### ABSTRACT

**Aim:** This study develops a quantitative ELISA for measuring Shiga toxin 2 (Stx2) produced by Shiga toxin (Stx)-producing *Escherichia coli* (STEC), including foodborne pathogen *E. coli* O157:H7 by all commercially available reagents.

**Background:** Most foodborne outbreak strains of STEC produce Stx2a, Stx2c or both, which are more frequently associated with human clinical cases, leading to severe gastrointestinal diseases or even death. However, no simple and cheap assays or kits are available for quantitative detection of Stx2a and Stx2c. Therefore, an easy and affordable quantitative method for Stx2 is needed for its pathogenesis study.

**Results:** We successfully developed a sensitive and specific receptor-based ELISA by using all commercial available agents. Hydroxyl acyl ceramide trihexoside, an analogue of Stx2 receptor globotriaosylceramide (Gb3), was used for antigen capture, and several critical steps were identified that must be adhered to ensure repeatability. No cross reactivity was observed with Stx1, and linear curves could be constructed using either purified Stx2a or a bacterial lysate from an Stx2a-producing *E. coli* O157:H7 strain. We applied this method to quantify Stx2 production by a collection of *E. coli* O157:H7 strains, indicating it can be extended to qualitatively evaluate Stx2c, and providing evidence that toxin production does not necessarily correlate with strain phylogeny.

**Conclusion:** Our R-ELISA provides a reliable way to quantify Stx2a using commercially available components, and it can also be used for detecting Stx2c. This cost-effective ELISA can be easily performed, suggesting it will be a useful tool for studying pathogenesis of STEC.

**KEY WORDS:** Shiga toxin-producing *E. coli*; *E. coli* O157:H7; ELISA; Shiga toxin 2.

**ABBREVIATIONS:** Stx: Shiga toxin; STEC: Stx-producing *Escherichia coli*; Gb3: Globotriaosylceramide; HC: Hemorrhagic Colitis; HUS: Hemolytic Uremic Syndrome; USDA: US Department of Agriculture; LSPA: Lineage Specific Polymorphism Assay.

### INTRODUCTION

Shiga toxin (Stx)-producing *Escherichia coli* (STEC) cause gastrointestinal diseases such as Hemorrhagic colitis (HC), and in some cases this develops into the life-threatening hemolytic uremic syndrome (HUS).<sup>1,2</sup> Foodborne pathogen, *E. coli* O157:H7, is a genetically heterogeneous serotype of STEC. Consumption of as low as ten cells of O157:H7 derived from contaminated bovine origin foods such as beef and cheese, people may develop symptoms ranging from asymptomatic carriage, bloody diarrhea, to fatal HUS. It has been estimated to cause 73,000 illnesses and 60 deaths annually in United States (US), with an estimated economic loss of about 400 million dollars. This pathogen continues to cause most of known outbreaks across the globe.<sup>3,4</sup> Therefore, the US Department of Agriculture (USDA) has enforced

a “zero tolerance policy” to regulate the prevalence of O157:H7 in foods. Genetic methods, most commonly the lineage specific polymorphism assay (LSPA)<sup>5</sup> and clade typing,<sup>6</sup> have been used to separate O157:H7 strains by virulence potential and ecology. For example, human isolates are more commonly classified as lineage I and I/II than lineage II,<sup>7,8</sup> and it has been argued that isolates from clades 6 and 8 are more virulent than isolates from other clades.<sup>6,9,10</sup>

Many virulence factors contribute to the pathogenesis of *E. coli* O157:H7 including Stx.<sup>11,12</sup> This is an AB<sub>5</sub> toxin, comprised of a single A subunit associated with 5 identical B subunits.<sup>13,14</sup> While the pentamer binds to Gb3 located in the host cell membrane,<sup>15</sup> the A subunit functions as a glycosidase, cleaving an adenine nucleotide from 28S rRNA within the 60S subunit. This results in inhibition of protein synthesis, followed by necrosis and cell death.<sup>16</sup> There are 2 immunologically distinct isoforms of the toxin, designated Stx1 and Stx2, which share 56.8% amino acid identity.<sup>17</sup> Stx2 has a lower affinity for Gb3 than Stx1<sup>18</sup>; however, Stx2 is more toxic in animal models<sup>19-21</sup> and associated with more severe clinical cases.<sup>22</sup> Among the seven subtypes of Stx2 (from Stx2a to Stx2g),<sup>23</sup> Stx2a and Stx2c are more often associated with clinical strains causing deadly HUS.<sup>24,25</sup> In this manuscript, we will use “Stx2” when collectively referring to its subtypes.

Stx2 producing strains are correlated with the development of HUS,<sup>26,27</sup> leading to the hypothesis that high toxin-producing strains are more likely to cause severe disease symptoms. Several studies have concluded, for example, that lineage I and I/II isolates produce more Stx2 than lineage II isolates,<sup>28</sup> and that clade 8 isolates are high toxin producers compared to isolates from other clades.<sup>29,30</sup> Most studies measure Stx2 production by semi-quantitative commercial kits,<sup>10</sup> qPCR/microarray,<sup>10,29,30</sup> or by semi-quantitative western blots.<sup>30</sup> Concerning mRNA quantification, several studies have reported that Stx2 transcript levels do not always correlate with Stx2 toxin production.<sup>10,30,31</sup> Thus, immunoassays are preferred methods for quantifying Stx production.

Several immunologic methods were previously described that use either immobilized antibodies specific for Stx,<sup>32,33</sup> or a receptor mimic<sup>34-36</sup> as the antigen capture in the sandwich ELISA. The disadvantage for the former is that it requires two sets of anti-Stx2 antibody from different species for both antigen capture and detection steps, while the latter assay only needs one set of anti-Stx2 antibody for detection. Most commercially available anti-Stx2 antibodies are monoclonal and generated from mice, so we suggest that one drawback preventing most research laboratories from quantifying Stx2 by sandwich ELISA is the limited commercial availability of antibodies from other species. Although, commercial kits such as Premier<sup>®</sup> Enterohemorrhagic *Escherichia coli* (EHEC) has been developed for detecting Stx, they are not designed to be specifically for Stx2 quantification, because they can not differentiate Stx1 from Stx2. Its high cost also prohibits most laboratories

from routinely using it for this purpose. Moreover, previously reported sandwich ELISA by using Gb3 as antigen capture was not developed to be quantitative for Stx2. Therefore, we were motivated to develop a cheap and reliable assay specifically for quantifying Stx2a that required only one set of anti-Stx2a antibody. Our initial attempts to develop a R-ELISA met with several difficulties in consistency and repeatability, an issue echoed in a previous publication.<sup>36</sup> We suggest here that development of a robust assay would require identifying and standardizing critical steps of this assay, so it can be successfully applied to quantify Stx2a.

## MATERIALS AND METHODS

### Strains and Culture Conditions

The fourteen *E. coli* O157:H7 strains used in this study were obtained from the Pennsylvania Department of Health and previously characterized by our lab.<sup>7</sup> They were stored in 10% glycerol at -80 °C.

### Ciprofloxacin Induction and Bacteria Lysate Collection

Each strain was propagated in Luria Broth (LB) at 37 °C with shaking overnight. Cells were diluted to A<sub>600</sub> of 0.05 in fresh LB broth. To induce toxin expression, ciprofloxacin was added to a sub-lethal concentration of 45 ng/mL. After an eight-hour incubation at 37 °C with shaking, the culture was centrifuged at 4,000 g for 10 min, and supernatants were filtered through 0.2 μM cellulose acetate filters (VWR, Radnor, PA, USA).

### Stx2 Specific R-ELISA

A 0.5 mg/ml stock solution of hydroxyl acyl ceramide trihexoside (Matreya Biosciences, Pleasant Gap, PA, USA) was prepared in chloroform: methanol (2:1, v/v). This stock solution was further diluted to 25 μg/mL in methanol, and was either used immediately or stored at -20 °C. Frozen stocks were heated in a 55 °C water bath to re-dissolve hydroxyl acyl CTH before use. To coat wells with antigen capture, a volume of 100 μL hydroxyl acyl CTH working solution was added to wells of an eight-well polystyrene strip plate (Thermo Scientific, Waltham, MA, USA) in a chemical fume hood. Strip plates were rotated manually every 15 minutes until the methanol was fully evaporated. Next, 200 μL blocking buffer [4% bovine serum albumin (BSA) in 0.01 M phosphate buffer saline (PBS) with 0.05% Tween20] was added to each well and incubated at 4 °C for 16 hours. After removing blocking buffer, 200 μL washing buffer (0.01M PBS with 0.05% Tween20) was added to each well and incubated for one minute on a shaking platform. This step was repeated for a total of 5 washes.

The R-ELISA assay was initiated by adding 100 μL sample into each well, followed by shaking at room temperature for one hour. Wells were washed five times in PBS/Tween20 as described above. Next, 100 μL mouse anti-Stx2 antibody (Santa

Cruz Biotech, Santa Cruz, CA, USA) was diluted in blocking buffer to 1  $\mu\text{g/mL}$ , added to each well, and incubated with shaking at room temperature for one hour. Wells were again washed five times with PBS/Tween20. Goat anti-mouse HRP conjugated secondary antibody was diluted in the blocking buffer (1  $\mu\text{g/mL}$ , 100  $\mu\text{L}$ ) and added to each well, and incubated with shaking at room temperature for one hour. Five washes in PBS/Tween20 followed; however, this time each wash was performed for five minutes. Detection was accomplished using 1-Step Ultra TMB (Thermo-Fischer, Waltham, MA, USA), which was equilibrated to room temperature in a foil-wrapped tube for at least 30 minutes prior to use. TMB substrate (100  $\mu\text{L}$ ) was added to each well and incubated with shaking for 10 minutes to allow for color development. Finally, 100  $\mu\text{L}$  of stop solution (2 M  $\text{H}_2\text{SO}_4$ ) was added to each well, followed by shaking for 30 seconds. The reading values of  $A_{450}$  were obtained using a DU<sup>®</sup>730 spectrophotometer (Beckman Coulter, Atlanta, Georgia, USA).

For all assays, supernatants from *E. coli* O157:H7 strain PA24, which produces only Stx1, were used for the negative control, and a lysate from a *E. coli* O157:H7 strain, PA11, served as the positive control. The Stx2a concentration for PA11 stock was quantified by known concentration of pure Stx2 (BEI Resources, Manassas, VA, USA). The standard curves in R-ELISA were generated using two-fold serially diluted PA11 lysate in PBS. Any  $A_{450}$  above 0.1 was considered as positive. Total

protein in each unknown sample was measured by the Bradford assay (VMR Life Science, Philadelphia, PA, USA), following the manufacturer's recommended protocol. Stx2 quantities were reported as  $\mu\text{g}$  Stx2/mg total protein.


### Statistic Analysis

All data were reported as the mean from three biological replicates and each sample had three technical repeats. The mean and standard error were calculated in MS Excel<sup>®</sup>. Data were analyzed using linear regression and one-way analysis of variance (ANOVA) in Minitab version 17 (Minitab Inc., State College, PA, USA).

## RESULTS

### Assay Optimization

We started to develop our R-ELISA based on the traditional sandwich ELISA. Although, polyclonal anti-Stx2 antibody from rabbit (BEI resource, Manassas, VA, USA) was tried as the antigen capture in our initial attempt, it gave very high background noise. Therefore, we replaced the capture antibody with a Gb3 chemical analogue, hydroxyl acyl ceramide trihexoside (CTH) (Figure 1). Mouse anti-Stx2 A subunit monoclonal antibody (Santa Cruz Biotech, Santa Cruz, CA, USA) was selected as the



primary antibody. As a result, we were able to reduce the background noise, by giving optical density at 450 nm ( $A_{450}$ ) less than 0.1 when measuring the negative control.

Using previous publications<sup>34,36</sup> as guidelines, several critical steps which were not explicitly stated in those manuscripts were identified and further improved to make our assay robust and quantitative. First, although several Gb3 receptor mimics are available (CTH is available as hydroxyl acyl, non-hydroxyl acyl and lyso-derivatives), we found that hydroxyl acyl CTH was best at capturing Stx2a at room temperature (Table S1). Second, although the supplier recommended methanol as the solvent, we found that dissolving hydroxyl acyl CTH first in chloroform:methanol (2:1), and further diluting in methanol to the working concentration gave the best results. Commercial hydroxyl acyl CTH better dissolved in the former without leaving any solid residual, and the signal got improved by average five times higher (Table S2). Third, we used detachable eight-well polystyrene strip plates instead of traditional 96-well plates. This minimized edge effects, a common observation with ELISA where peripheral wells give a higher absorbance than central wells. Fourth, the coating of R-ELISA plate wells with hydroxyl acyl CTH needs to be performed as rapidly as possible, so evaporation of methanol occurs evenly across the wells. Last, each of the washing steps used to remove the secondary antibody was extended to five minutes to minimize background noise.

#### Specificity and Sensitivity of Stx2 Specific R-ELISA


The specificity of this assay was first tested by using bacteria lysate of Stx1-producing strain previously designated PA24.<sup>7</sup> The absorbance at 450 nm ( $A_{450}$ ) for bacteria lysate from PA24 is routinely less than 0.1, indicating that no cross-reactivity was observed in this assay with Stx1. As pure Stx2a from biodefense and emerging infectious (BEI) resource is available in quite limited quantity, we decided to use lysates from a high Stx2a-

producing strain previously designated PA11<sup>7</sup> as the toxin source for standard curves. The Stx2a concentration in PA11 supernatants after ciprofloxacin induction was first quantified by using known concentration of pure Stx2a and around 23.2  $\mu\text{g/mL}$ . We routinely obtained a linear range between an  $A_{450}$  of 0.3 to 3.2, corresponding to a Stx2a concentration from 23 ng/mL to 363 ng/mL (Figure 2).

#### Application of Stx2 Specific R-ELISA to Quantify Toxin in Bacteria Lysates

This assay was designed specifically for Stx2a. Although, Stx2a and Stx2c were reported to vary in their affinities to Gb3 *in vitro*, we expected this assay to detect Stx2c because the primary antibody used targets at the A subunit of Stx2, which is conserved between the 2 subtypes.<sup>23,37</sup> Therefore, we next evaluated whether this assay could be applied to measure the Stx2 levels in bacteria lysates from phylogenetically distinct strains. Thirteen strains from 6 of the known nine clades (Table 1) were chosen. These strains consisted of four defined Stx-allelic types: Stx2a only, Stx2c only, Stx1 & 2c and Stx2a & 2c previously.<sup>7</sup> One strain (PA7) was previously reported to be Stx1 and Stx2 negative by polymerase chain reaction (PCR), although it was toxin-positive using Premier<sup>®</sup> EHEC that simultaneously detected both isoforms; and another strain (PA48) could not be categorized by lineage subtype method. We quantified Stx2 in eleven of the thirteen strains (Figure 3), with strains PA7 and PA48 under the detection limit. Therefore, this assay could be applied to detect Stx2c levels in bacteria lysates of strains harboring either Stx2c (PA38, 40) or both Stx2c and Stx1 (PA22, 41).


Among them, the highest producer (PA39) had approximately five times more Stx2 production than the lowest strain (PA5). Strains sharing the same lineage, clade or Stx allelic type showed varied Stx2 levels as well. For example, strains PA32, 49 from lineage I produced similar amounts of Stx2 as PA31, but significantly more than lineage I strain PA5. Likewise, among



**Table 1: Characteristics Summary of STEC Strains Used in this Study.**

Clade type	Toxin profile	Strain name	Lineage type*
Clade 2	Stx2a	PA 32	lineage I
Clade 2	Stx1 & 2a	PA 5, 31, 49	lineage I
Clade 5	Stx1 & 2c	PA 22	lineage I/II
Clade 6	Stx2c	PA 38	lineage I/II
Clade 7	Stx2c	PA 40	lineage II
Clade 7	Stx1 & 2c	PA 41	lineage II
Clade 8	Stx1	PA 24	lineage I/II
Clade 8	Stx2a & 2c	PA 35, 39, 47	lineage I/II
Clade 9	Stx1 & 2c	PA 48	Undefined
Unclassified	Unknown	PA 7	lineage I

\*The lineage and Stx profiles of all strains were previously reported.<sup>7</sup>



the three strains in clade 8, the Stx2 level in strain PA39 was similar to PA47; however, significantly higher than PA35. Lastly, among strains producing both Stx1 and Stx2a, strain PA49 produced significantly higher amounts of toxin than strain PA5, but was not different from PA31.

**DISCUSSION**

Stx2a and Stx2c are responsible for severe clinical complications such as life-threatening HUS caused by foodborne pathogen *E. coli* O157:H7. Thus, the accurate measurement of Stx2 production is important to study its pathogenesis. A globotetraosylceramide (Gb4)-based ELISA was reported for quantitative detection of Stx2e<sup>38</sup>; however, it can not be applied to measure other Stx2 subtypes because the latter preferentially recognize different receptor, Gb3. Therefore, no quantitative receptor-based

ELISA was available for measuring Stx2a before our study by using all commercial available agents. In this study, we have developed a robust assay for the quantification for Stx2a, and it is also expected to detect Stx2c. The cost for this quantitative assay is one third of qualitative Premier<sup>®</sup> EHEC kit.

Although, Gb3 have been used previously in immunoassays to capture Stx,<sup>35,36</sup> we identified several steps that were critical to follow in order to achieve repeatable results. In addition, there are three other modifications from the literature worth highlighting. First, it was reported that the lysoform of Gb3 provided more reliable Stx1 detection, presumably because it is less hydrophobic.<sup>36</sup> However, during assay development we found that lyso-CTH was less effective at capturing Stx2a than hydroxyl acyl CTH. When testing the same bacteria lysate from O157:H7 strain with a high Stx2a concentration, the hydroxyl

acyl CTH gave saturated reading while the  $A_{450}$  for lyso-CTH is as low as negative control (Table S1). This could simply reflect differences in affinity of Stx1 and Stx2a for CTH derivatives. Secondly, another group previously reported that they could improve R-ELISA sensitivity by increasing the amount of receptor used to coat wells.<sup>36</sup> While we saw similar results in initial trials, we decided that 25  $\mu\text{g/ml}$  hydroxyl acyl CTH was the optimal concentration for detecting Stx2a. Under this concentration, we were able to detect Stx2a as low as 23 ng/mL which met our need. In Gb4-based quantitative ELISA for Stx2e, the limit of detection is 20 ng/mL,<sup>38</sup> as comparable as ours. Moreover, two 96 well R-ELISA plates can be prepared from one vial of commercial available CTH (0.5 mg), instead of one 96 well plate if a higher concentration was used. Lastly, it was reported that the presence of cholesterol alone or along with lecithin caused statistically significant increases in the binding of Gb3 to Stx2.<sup>39</sup> However, no enhancement of Stx2a capture was found when combining these with hydroxyl acyl CTH during the coating step.

Using R-ELISA, we were able to quantify toxin levels from various *E. coli* O157:H7 strains, and obtained results that were both confirmed and contrasted with those previously reported. First, we did not notice a correlation between Stx2 production and lineage. It was previously reported that *E. coli* O157:H7 isolates from lineage II produced less Stx2 than those from lineage I and I/II<sup>28</sup>; however, our findings show that the Stx2 levels in strains from lineage II (PA40, 41) were not significantly different from strains belonging to lineage I (PA5, 31, 32, 49) or lineage I/II (PA22, 35, 38, 47). Second, although strains from clade 8 were suggested to produce higher Stx2 levels than isolates from other clades,<sup>29,30</sup> our data indicates this is not universal. In our study, clade 8 strain PA35 produced similar amounts of Stx2 as others clades, including clade 2 (PA31), clade 5 (22), clade 6 (PA38) and clade 7 (PA40, 41). Lastly, it was previously suggested that Stx2-only producing strains synthesized more toxin than Stx1/Stx2-producers, due to crosstalk between phage-encoded repressors encoded in different Shiga toxin-converting phages.<sup>40</sup> However, the Stx2a-only strain PA32 produced toxin level that was similar to most Stx1/Stx2-producing strains we tested. It appears likely that phylogeny or toxin profile alone does not explain differences in toxin levels and thus virulence differences observed among strains. More factors such as colonization, adherence capabilities and other virulence genes, need to be considered as well.

Two strains, PA7 and PA48, produced Stx2 levels that were below the detectable limit using our R-ELISA. Strain PA48 is classified as clade 9, and was previously shown to be LSPA type 311111.<sup>7</sup> This strain is related to *E. coli* O157:H7 strain G5101,<sup>41</sup> which is also LSPA 311111<sup>42</sup> and is atypical among pathogens of this serotype in that it is  $\beta$ -glucuronidase-positive. Little is known about the toxin production levels of these strains. PA7 is a strain previously characterized<sup>7</sup> and identified as PCR-negative for both Stx1 and Stx2; however, the commercial kit that simultaneously detects both subtypes identified this strain

as Shiga toxin-positive. Our results here suggest the commercial assay was detecting Stx1, although it is possible that PA7 produces Stx2 level below the limit of detection of our R-ELISA.

While this assay is useful for quantifying Stx2a in the bacterial lysates, we have observed limitations when applying it to environmental samples. In a previous publication,<sup>43</sup> we were unsuccessful using this method to quantify toxin levels in cattle mucus; however, we could accomplish this using the Premier EHEC kit sold by Meridian Biosciences, Cincinnati, OH, USA. We also found that our assay was one tenth less sensitive than the commercial kit for mouse feces. The sensitivity of the ELISA may be improved by using more hydroxyl acyl CTH as the receptor, or optimizing sample preparation steps to remove inhibitory components from these samples. Therefore, this R-ELISA may not be practical at the moment for detecting toxin in complex biological matrixes. However, it is advantageous when one needs to quantify toxin from laboratory samples while it is impractical to generate or obtain antibodies needed for a traditional sandwich ELISA.

## CONCLUSION

Our R-ELISA provides a reliable way to quantify Stx2a using commercially available components, and it can also be used for detecting Stx2c. The application of this assay can be expanded to other Stx2 subtype once corresponding pure toxin is available. It is a readily easy and cheap way to quantify toxin levels especially for groups that currently assess toxin production by qPCR or other transcription-based methods. We predict a similar quantitative assay can be developed to detect Stx1, although as stated above this may require selecting a different receptor mimic.

## ACKNOWLEDGEMENTS

We thank Joselyn N. Allen (Pennsylvania State University) for creating the scientific illustration for R-ELISA in this publication; Hillary M. Figler for proofreading this manuscript; M-treya LLC for technical assistance. This work was funded by USDA-NIFA grant 2010-65201-20619.

## CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

## REFERENCES

1. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing *Escherichia coli* and haemolytic uraemic syndrome. *Lancet*. 2005; 365: 1073-1086. doi: [10.1016/S0140-6736\(05\)71144-2](https://doi.org/10.1016/S0140-6736(05)71144-2)
2. Scheiring J, Andreoli SP, Zimmerhackl LB. Treatment and outcome of Shiga toxin-associated hemolytic uremic syndrome (HUS). *Pediatr Nephrol*. 2008; 23: 1749-1760. doi: [10.1007/s00467-008-0935-6](https://doi.org/10.1007/s00467-008-0935-6)

3. Heiman KE, Mody RK, Johnson SD, Griffin PM, Gould LH. *Escherichia coli* O157 outbreaks in the United States, 2003-2012. *Emerg Infect Diseases*. 2015; 21: 1293-1301. doi: [10.3201/eid2108.141364](https://doi.org/10.3201/eid2108.141364)
4. Locking ME, Pollock KGJ, Allison LJ, Rae, L, Hanson MF, Cowden JM. *Escherichia coli* O157 infection and secondary spread, Scotland, 1999-2008. *Emerg Infect Dis*. 2011; 17: 524-527. doi: [10.3201/eid1703.100167](https://doi.org/10.3201/eid1703.100167)
5. Kim J, Nietfeldt J, Benson AK. Octamer-based genome scanning distinguishes a unique subpopulation of *Escherichia coli* O157:H7 strains in cattle. *Proc Natl Acad Sci U S A*. 1999; 96: 13288-13293. doi: [10.1073/pnas.96.23.13288](https://doi.org/10.1073/pnas.96.23.13288)
6. Manning SD, Motiwala AS, Springman AC, et al. Variation in virulence among clades of *Escherichia coli* O157:H7 associated with disease outbreaks. *Proc Natl Acad Sci U S A*. 2008; 105: 4868-4873. doi: [10.1073/pnas.0710834105](https://doi.org/10.1073/pnas.0710834105)
7. Hartzell A, Chen C, Lewis C, Liu K, Reynolds S, Dudley EG. *Escherichia coli* O157:H7 of genotype lineage-specific polymorphism assay 211111 and clade 8 are common clinical isolates within Pennsylvania. *Foodborne Pathog Dis*. 2011; 8: 763-768. doi: [10.1089/fpd.2010.0762](https://doi.org/10.1089/fpd.2010.0762)
8. Mellor GE, Besser TE, Davis MA, et al. Multilocus genotype analysis of *Escherichia coli* O157 Isolates from Australia and the United States provides evidence of geographic divergence. *Appl Environ Microbiol*. 2013; 79: 5050-5058. doi: [10.1128/AEM.01525-13](https://doi.org/10.1128/AEM.01525-13)
9. Iyoda S, Manning SD, Seto K, et al. Phylogenetic clades 6 and 8 of enterohemorrhagic O157:H7 with particular Stx subtypes are more frequently found in isolates from HUS patients than from asymptomatic carrier. *Open Forum Infect Dis*. 2014; 6: 1-8.
10. Amigo N, Mercado E, Bentancor A, et al. Clade 8 and clade 6 strains of *Escherichia coli* O157:H7 from cattle in Argentina have hypervirulent-like phenotypes. *PLoS One*. 2015; 10: e0127710. doi: [10.1371/journal.pone.0127710](https://doi.org/10.1371/journal.pone.0127710)
11. Karch FH, Heesemann J, Laufs R, Brien ADO, Tacket C, Levine MM. A Plasmid of enterohemorrhagic *Escherichia coli* O157 : H7 is required for expression of a new fimbrial antigen and for adhesion to epithelial cells. *Infect Immun*. 1987; 55: 455-461.
12. Donnenberg MS, Tzipori S, McKee ML, O'Brien AD, Alroy J, Kaper JB. The role of the *eae* gene of enterohemorrhagic *Escherichia coli* in intimate attachment *in vitro* and in a porcine model. *J Clin Invest*. 1993; 92: 1418-1424. doi: [10.1172/JCI116718](https://doi.org/10.1172/JCI116718)
13. Mauro SA, Koudelka GB. Shiga toxin: Expression, distribution, and its role in the environment. *Toxins*. 2011; 3: 608-625. doi: [10.3390/toxins3060608](https://doi.org/10.3390/toxins3060608)
14. Fraser ME, Fujinaga M, Cherney MM, et al. Structure of Shiga toxin type 2 (Stx2) from *Escherichia coli* O157:H7. *J Biol Chem*. 2004; 279: 27511-27517. doi: [10.1074/jbc.M401939200](https://doi.org/10.1074/jbc.M401939200)
15. Waddell T, Cohen A, Lingwood CA. Induction of verotoxin sensitivity in receptor-deficient cell lines using the receptor glycolipid globotriosylceramide. *Proc Natl Acad Sci U S A*. 1990; 87: 7898-7901. doi: [10.1073/pnas.87.20.7898](https://doi.org/10.1073/pnas.87.20.7898)
16. Schüller S. Shiga toxin interaction with human intestinal epithelium. *Toxins*. 2011; 3: 626-639. doi: [10.3390/toxins3060626](https://doi.org/10.3390/toxins3060626)
17. Tesh VL, O'Brien AD. The pathogenic mechanisms of Shiga toxin and the Shiga-like toxins. *Mol Microbiol*. 1991; 5: 1817-1822. doi: [10.1111/j.1365-2958.1991.tb00805.x](https://doi.org/10.1111/j.1365-2958.1991.tb00805.x)
18. Head SC, Karmalisg MA, Lingwood CA. Preparation of VT1 and VT2 hybrid toxins from their purified dissociated subunits. *J Biol Chem*. 1991; 6: 3617-3621.
19. Rutjes NWP, Binnington BA, Smith CR, Maloney MD, Lingwood CA. Differential tissue targeting and pathogenesis of verotoxins 1 and 2 in the mouse animal model. *Kidney Int*. 2002; 62: 832-845. doi: [10.1046/j.1523-1755.2002.00502.x](https://doi.org/10.1046/j.1523-1755.2002.00502.x)
20. Siegler RL, Obrig TG, Pysher TJ, Tesh VL, Denkers ND, Taylor FB. Response to Shiga toxin 1 and 2 in a baboon model of hemolytic uremic syndrome. *Pediatr Nephrol*. 2003; 18: 92-96. doi: [10.1007/s00467-002-1035-7](https://doi.org/10.1007/s00467-002-1035-7)
21. Tesh VL, Burris JA, Owens JW, et al. Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice. *Infect Immun*. 1993; 61: 3392-3402.
22. Kawano K, Okada M, Haga T, Maeda K, Goto Y. Relationship between pathogenicity for humans and Stx genotype in Shiga toxin-producing *Escherichia coli* serotype O157. *Eur J Clin Microbiol Infect Dis*. 2008; 27: 227-232. doi: [10.1007/s10096-007-0420-3](https://doi.org/10.1007/s10096-007-0420-3)
23. Scheutz F, Teel LD, Beutin L, et al. Multicenter evaluation of a sequence-based protocol for subtyping Shiga toxins and standardizing Stx nomenclature. *J Clin Microbiol*. 2012; 50: 2951-2963. doi: [10.1128/JCM.00860-12](https://doi.org/10.1128/JCM.00860-12)
24. Friedrich AW, Bielaszewska M, Zhang WL, et al. *Escherichia coli* harboring Shiga toxin 2 gene variants: Frequency and association with clinical symptoms. *J Infect Dis*. 2002; 185: 74-84. doi: [10.1086/338115](https://doi.org/10.1086/338115)
25. Persson S, Olsen KEP, Ethelberg S, Scheutz F. Subtyping method for *Escherichia coli* Shiga toxin (verocytotoxin) 2 variants and correlations to clinical manifestations. *J Clin Microbiol*. 2007; 45: 2020-2024. doi: [10.1128/JCM.02591-06](https://doi.org/10.1128/JCM.02591-06)
26. Boerlin P, McEwen SA, Boerlin-Petzold F, Wilson JB, Johnson RP, Gyles CL. Associations between virulence factors of

- Shiga toxin-producing *Escherichia coli* and disease in humans. *J Clin Microbiol.* 1999; 37: 497-503.
27. Ethelberg S, Olsen KEP, Scheutz F, et al. Virulence factors for hemolytic uremic syndrome, Denmark. *Emerg Infect Dis.* 2004; 10: 842-847. doi: [10.3201/eid1005.030576](https://doi.org/10.3201/eid1005.030576)
28. Zhang Y, Laing C, Zhang Z, et al. Lineage and host source are both correlated with levels of Shiga toxin 2 production by *Escherichia coli* O157:H7 strains. *Appl Environ Microbiol.* 2010; 76: 474-482. doi: [10.1128/AEM.01288-09](https://doi.org/10.1128/AEM.01288-09)
29. Abu-Ali GS, Ouellette LM, Henderson ST, et al. Increased adherence and expression of virulence genes in a lineage of *Escherichia coli* O157:H7 commonly associated with human infections. *PLoS One.* 2010; 5: 1-10. doi: [10.1371/journal.pone.0010167](https://doi.org/10.1371/journal.pone.0010167)
30. Neupane M, Abu-Ali GS, Mitra A, Lacher DW, Manning SD, Riordan JT. Shiga toxin 2 overexpression in *Escherichia coli* O157:H7 strains associated with severe human disease. *Microb Pathog.* 2011; 51: 466-470. doi: [10.1016/j.micpath.2011.07.009](https://doi.org/10.1016/j.micpath.2011.07.009)
31. Yin S, Rusconi B, Sanjar F, et al. *Escherichia coli* O157:H7 strains harbor at least three distinct sequence types of Shiga toxin 2a-converting phages. *BMC Genomics.* 2015; 16: 733-746. doi: [10.1186/s12864-015-1934-1](https://doi.org/10.1186/s12864-015-1934-1)
32. Ball HJ, Finlay D, Zafar A, Wilson T. The detection of verocytotoxins in bacterial cultures from human diarrhoeal samples with monoclonal antibody-based ELISAs. *J Med Microbiol.* 1996; 44: 273-276. doi: [10.1099/00222615-44-4-273](https://doi.org/10.1099/00222615-44-4-273)
33. He X, Patfield S, Hnasko R, Rasooly R, Mandrell RE. A polyclonal antibody based immunoassay detects seven subtypes of Shiga toxin 2 produced by *Escherichia coli* in human and environmental samples. *PLoS One.* 2013; 8: e76368. doi: [10.1371/journal.pone.0076368](https://doi.org/10.1371/journal.pone.0076368)
34. Ashkenazi S, Cleary TG. Rapid method to detect Shiga toxin and Shiga-like toxin I based on binding to globotriosyl ceramide (Gb3), their natural receptor. *J Clin Microbiol.* 1989; 27: 1145-1150.
35. Acheson DW, Jacewicz M, Kane AV, Donohue-Rolfe A, Keusch GT. One step high yield affinity purification of Shiga-like toxin II variants and quantitation using enzyme linked immunosorbent assays. *Microb Pathog.* 1993; 14: 57-66. doi: [10.1006/mpat.1993.1006](https://doi.org/10.1006/mpat.1993.1006)
36. Basta M, Karmali M, Lingwood C. Sensitive receptor-specified enzyme-linked immunosorbent assay for *Escherichia coli* verocytotoxin. *J Clin Microbiol.* 1989; 27: 1617-1622.
37. Strauch E, Schaudinn C, Beutin L. First-time isolation and characterization of a bacteriophage encoding the Shiga toxin 2c variant, which is globally spread in strains of *Escherichia coli* O157. *Infect Immun.* 2004; 72: 7030-7039. doi: [10.1128/IAI.72.12.7030-7039.2004](https://doi.org/10.1128/IAI.72.12.7030-7039.2004)
38. Togashi K, Sasaki S, Sato W. A globotetraosylceramide (Gb4) receptor-based ELISA for quantitative detection of Shiga toxin 2e. *J Vet Med Sci.* 2015; 77: 973-976. doi: [10.1292/jvms.14-0071](https://doi.org/10.1292/jvms.14-0071)
39. Gallegos KM, Conrady DG, Karve SS, Gunasekera TS, Herr AB, Weiss AA. Shiga toxin binding to glycolipids and glycans. *PLoS One.* 2012; 7: e30368. doi: [10.1371/journal.pone.0030368](https://doi.org/10.1371/journal.pone.0030368)
40. Serra-Moreno R, Jofre J, Muniesa M. The CI repressors of Shiga toxin-converting prophages are involved in coinfection of *Escherichia coli* strains, which causes a down regulation in the production of Shiga toxin 2. *J Bacteriol.* 2008; 190: 4722-4735. doi: [10.1128/JB.00069-08](https://doi.org/10.1128/JB.00069-08)
41. Hayes PS, Blom K, Feng P, Lewis J, Strockbine NA, Swaminathan B. Isolation and characterization of a beta-D-glucuronidase-producing strain of *Escherichia coli* serotype O157:H7 in the United States. *J Clin Microbiol.* 1995; 33: 3347-3348.
42. Liu K, Knabel SJ, Dudley EG. *rhs* genes are potential markers for multilocus sequence typing of *Escherichia coli* O157:H7 strains. *Appl Environ Microbiol.* 2009; 75: 5853-5862. doi: [10.1128/AEM.00859-09](https://doi.org/10.1128/AEM.00859-09)
43. Goswami K, Chen C, Xiaoli L, Eaton KA, Dudley EG. Co-culture of *Escherichia coli* O157:H7 with a nonpathogenic *E. coli* strain increases toxin production and virulence in a germ-free mouse model. *Infect Immun.* 2015; 83: 4185-4193. doi: [10.1128/IAI.00663-15](https://doi.org/10.1128/IAI.00663-15)

**SUPPLEMENTARY DATA**

**Table S1:** The A450 for CTH Derivatives as Receptors in ELISA. The Data was Showed in Mean±Standard Deviation and Derived from Three Prelicates.

Stx2a concentration (ng/mL)	Hydroxyl acyl CTH	Non hydroxyl acyl CTH	Lyso CTH
240.0	2.8639±0.0132	0.0909±0.0122	0.1011±0.0097
120.0	1.8045±0.0115	0.0809±0.0106	0.0878±0.0072
60.0	0.9532±0.0107	0.0838±0.0094	0.0987±0.0080
30.0	0.5854±0.0091	0.0946±0.1010	0.0891± 0.0090
0	0.1012±0.0041 (negative control)		

**Table S2:** The A450 for Using Different Solvents for Dissolving CTH. The Data was Showed in Mean±Standard Deviation and Derived from Three Prelicates.

Stx2a Concentration (ng/mL)	Chloroform: Methanol	Methanol
240.0	2.8639±0.0132	0.5788±0.114
120.0	1.8045±0.0115	0.3224±0.090
60.0	0.9532±0.0107	0.1632±0.120
30.0	0.5854±0.0091	0.1232±0.098